1-3 of 3
Peter Bias
Close
Sort by
Journal Articles

A Phase 2, International, Multicenter, Prospective Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients with Solid Tumors Undergoing Chemotherapy

Noah Federman, Monica Desiree Dragomir, Zoryana Kizyma, Vladimir Lebedev, Jelena Roganovic, Peter Bias, Andreas Lammerich, Zipi Roth-Ben Arie, Linglong Zou, Anton Buchner
Journal: Blood
Blood (2017) 130 (Supplement 1): 2271.
https://doi.org/10.1182/blood.V130.Suppl_1.2271.2271
Published: 2017
Journal Articles

GlycoPEGylated Filgrastim XM22 Demonstrates Dose-Dependent Activity in Comparison to Pegfilgrastim in a Dose-Escalating Study in Healthy Volunteers after Body-Weight Dependent Single Dose.

Heinz Lubenau, PhD, Rolf Pokorny, MD, Luis Lopez-Lazaro, MD, Peter Bias, MD, Bruce Wallin, MD, Walter Hinderer, PhD, Anne-Katrin Maly, Michael Seiberling, MD
Journal: Blood
Blood (2007) 110 (11): 4081.
https://doi.org/10.1182/blood.V110.11.4081.4081
Published: 2007
Journal Articles

GlycoPEGylated Filgrastim XM22 Fixed Dose Demonstrates Similar Activity in Comparison to Pegfilgrastim in Healthy Volunteers after Single Administration.

Heinz Lubenau, PhD, Rolf Pokorny, MD, Luis Lopez-Lazaro, MD, Peter Bias, MD, Bruce Wallin, MD, Walter Hinderer, PhD, Anne-Katrin Maly, Michael Seiberling, MD
Journal: Blood
Blood (2007) 110 (11): 4082.
https://doi.org/10.1182/blood.V110.11.4082.4082
Published: 2007